Role of Beta-Blockers Following Percutaneous Balloon Pulmonary Valvuloplasty

Abstract

ongenital heart malformations are the most frequent of all major birth defects, with an estimated prevalence at birth of approximately 8-10 cases per 1000 births. Amongst congenital heart disease, pulmonary valve stenosis (PS) accounts for 10% of congenital heart diseases and is accompanied in approximately 20% of congenital heart disease cases. The traditional treatment for pulmonary valve stenosis prior was surgical valvotomy. Nowadays balloon pulmonary valvuloplasty has become the treatment of choice for relief of pulmonary valve stenosis. One of the complications noticed post-BPV is the right ventricular outflow tract (RVOT) obstruction resulting in residual dynamic gradient across the right ventricular infundibulum. Such complication may become quite significant and lead to the so-called “suicide RV”.